AEON Biopharma closed at $0.21 on Nov 4, down 1.70%, 84.7% below its 52-week closing high. Volume of 6.6M shares was 8.42× its 20-day average (well above normal).
Split-adjusted performance: -28.0% over one month, -77.0% over six months, -77.1% over one year.
Short interest was 3.3M shares at the Oct 15 settlement, up 49.7% from the prior report (28.5% of float, 1.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AEONAEON Biopharma | $0.2086 | −1.70% | −77.0% | — | — | — | $12.3M | |
| HINDVyome Holdings | $1.74 | −1.93% | −21.1% | — | −2543.3% | — | $12.2M | Compare |
| LPCNLipocine | $1.44 | −1.37% | −40.7% | −100.0% | — | — | $11.9M | Compare |
| DAREDare Bioscience | $0.6619 | +1.83% | −79.1% | — | −1590.4% | — | $13.0M | Compare |
| BIVIBioVie | $1.34 | −22.54% | −19.3% | — | — | — | $11.6M | Compare |
| CLRBCellectar Biosciences INC NEW | $1.23 | −6.11% | −65.2% | — | — | — | $11.6M | Compare |
| TVRDTvardi Therapeutics | $0.8614 | +3.17% | −76.5% | — | — | — | $11.5M | Compare |
| LSTALisata Therapeutics | $1.06 | −2.75% | −67.5% | −100.0% | — | — | $11.5M | Compare |
| BFRIBiofrontera | $0.9038 | +1.56% | −20.7% | +32.9% | −5.0% | — | $13.4M | Compare |
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
